Paul J. Hagerman, M.D., Ph.D.

Dr. Hagerman

Position Title
Professor, Director, NeuroTherapeutics Research Institute (NTRI)

Unit
Biological Chemistry and Molecular Medicine


Bio

CLARITY and STED shed light on neurodegenerative disorders

Investigating ways to identify the initial triggering events that give rise to the neurodegenerative disorder fragile X-associated tremor/ataxia syndrome (FXTAS) will be the focus of this team. FXTAS may be one of the most common adult-onset, single-gene neurological diseases. Symptoms include tremors, instability, and difficulty with coordinated muscle movements like walking. Hagerman’s group plans to employ a novel genetic sequencing approach in combination with state-of-the-art microscopy imaging to better understand the mechanisms and pathways that lead to the disease, which could later serve as a starting point for therapeutic intervention.

Tags